Rapid Chagas Disease Drug Target Discovery Using Directed Evolution in Drug-Sensitive Yeast.

Recent advances in cell-based, high-throughput phenotypic screening have identified new chemical compounds that are active against eukaryotic pathogens. A challenge to their future development lies in identifying these compounds' molecular targets and binding modes. In particular, subsequent structure-based chemical optimization and target-based screening require a detailed understanding of the binding event. Here, we use directed evolution and whole-genome sequencing of a drug-sensitive S. cerevisiae strain to identify the yeast ortholog of TcCyp51, lanosterol-14-alpha-demethylase (TcCyp51), as the target of MMV001239, a benzamide compound with activity against Trypanosoma cruzi, the etiological agent of Chagas disease. We show that parasites treated with MMV0001239 phenocopy parasites treated with another TcCyp51 inhibitor, posaconazole, accumulating both lanosterol and eburicol. Direct drug-protein binding of MMV0001239 was confirmed through spectrophotometric binding assays and X-ray crystallography, revealing a binding site shared with other antitrypanosomal compounds that target Cyp51. These studies provide a new probe chemotype for TcCyp51 inhibition.

[1]  F. Buckner,et al.  Recent Developments in Sterol 14-demethylase Inhibitors for Chagas Disease. , 2012, International journal for parasitology. Drugs and drug resistance.

[2]  Jörg Schultz,et al.  HMM Logos for visualization of protein families , 2004, BMC Bioinformatics.

[3]  W. L. Jorgensen,et al.  Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .

[4]  J. Urbina,et al.  Ergosterol biosynthesis and drug development for Chagas disease. , 2009, Memorias do Instituto Oswaldo Cruz.

[5]  Michelle R. Arkin,et al.  Diverse Inhibitor Chemotypes Targeting Trypanosoma cruzi CYP51 , 2012, PLoS neglected tropical diseases.

[6]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[7]  M. Waterman,et al.  Sterol 14alpha-demethylase (CYP51) as a therapeutic target for human trypanosomiasis and leishmaniasis. , 2011, Current topics in medicinal chemistry.

[8]  J. Gut,et al.  4-Aminopyridyl-Based CYP51 Inhibitors as Anti-Trypanosoma cruzi Drug Leads with Improved Pharmacokinetic Profile and in Vivo Potency , 2014, Journal of medicinal chemistry.

[9]  F. Supek,et al.  Antitrypanosomal Treatment with Benznidazole Is Superior to Posaconazole Regimens in Mouse Models of Chagas Disease , 2015, Antimicrobial Agents and Chemotherapy.

[10]  Fernán Agüero,et al.  Genetic Profiling of the Isoprenoid and Sterol Biosynthesis Pathway Genes of Trypanosoma cruzi , 2014, PloS one.

[11]  Alejandro Sanchez-Flores,et al.  High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome. , 2011, Genome research.

[12]  S. Yusuf,et al.  The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. , 2009, Memorias do Instituto Oswaldo Cruz.

[13]  Jan H. Jensen,et al.  PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions. , 2011, Journal of chemical theory and computation.

[14]  Tom Alber,et al.  Automated protein crystal structure determination using ELVES. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[16]  R. Schiestl,et al.  High efficiency transformation of intact yeast cells using single stranded nucleic acids as a carrier , 1989, Current Genetics.

[17]  T. Sutter,et al.  Primary structure of the P450 lanosterol demethylase gene from Saccharomyces cerevisiae. , 1987, DNA.

[18]  J. Heitman,et al.  Ergosterol Biosynthesis Inhibitors Become Fungicidal when Combined with Calcineurin Inhibitors against Candida albicans, Candida glabrata, and Candida krusei , 2003, Antimicrobial Agents and Chemotherapy.

[19]  Jeffrey A. Porter,et al.  An Integrated Approach for Identification and Target Validation of Antifungal Compounds Active against Erg11p , 2012, Antimicrobial Agents and Chemotherapy.

[20]  John A. Tallarico,et al.  High-resolution chemical dissection of a model eukaryote reveals targets, pathways and gene functions. , 2014, Microbiological research.

[21]  S. Boyle,et al.  Cloning and analysis of Trypanosoma cruzi lanosterol 14α-demethylase , 2003 .

[22]  Richard A. Friesner,et al.  Flexible ligand docking with Glide. , 2007, Current protocols in bioinformatics.

[23]  P. Le Pape,et al.  Amino acid substitutions in the Candida albicans sterol Δ5,6-desaturase (Erg3p) confer azole resistance: characterization of two novel mutants with impaired virulence. , 2012, The Journal of antimicrobial chemotherapy.

[24]  L. Maes,et al.  Repurposing of the Open Access Malaria Box for Kinetoplastid Diseases Identifies Novel Active Scaffolds against Trypanosomatids , 2015, Journal of biomolecular screening.

[25]  J. Urbina,et al.  Sterol composition and biosynthesis in Trypanosoma cruzi amastigotes. , 1999, Molecular and biochemical parasitology.

[26]  M. Waterman,et al.  Small-Molecule Scaffolds for CYP51 Inhibitors Identified by High-Throughput Screening and Defined by X-Ray Crystallography , 2007, Antimicrobial Agents and Chemotherapy.

[27]  John A. Tallarico,et al.  Selective and Specific Inhibition of the Plasmodium falciparum Lysyl-tRNA Synthetase by the Fungal Secondary Metabolite Cladosporin , 2012, Cell host & microbe.

[28]  John R. Walker,et al.  Identification of pathogen genomic variants through an integrated pipeline , 2014, BMC Bioinformatics.

[29]  Mark C. Field,et al.  Modulation of the Surface Proteome through Multiple Ubiquitylation Pathways in African Trypanosomes , 2015, PLoS pathogens.

[30]  Yo Suzuki,et al.  Cloning Should Be Simple: Escherichia coli DH5α-Mediated Assembly of Multiple DNA Fragments with Short End Homologies , 2015, PloS one.

[31]  D. Horn.  High‐Throughput Decoding of Drug‐Targets and Drug‐Resistance Mechansims in African Trypanosomes , 2013, Parasitology.

[32]  J. Tyndall,et al.  Structural Insights into Binding of the Antifungal Drug Fluconazole to Saccharomyces cerevisiae Lanosterol 14α-Demethylase , 2015, Antimicrobial Agents and Chemotherapy.

[33]  F. Supek,et al.  Utilizing Chemical Genomics to Identify Cytochrome b as a Novel Drug Target for Chagas Disease , 2015, PLoS pathogens.

[34]  J. Altcheh,et al.  Adverse Events After the Use of Benznidazole in Infants and Children With Chagas Disease , 2011, Pediatrics.

[35]  W. de Souza,et al.  Sterol Biosynthesis Pathway as an Alternative for the Anti-Protozoan Parasite Chemotherapy. , 2015, Current medicinal chemistry.

[36]  G. Drewes,et al.  The enhanced ATPase activity of glutathione-substituted actin provides a quantitative approach to filament stabilization. , 1990, The Journal of biological chemistry.

[37]  J. Gut,et al.  Binding Mode and Potency of N-Indolyloxopyridinyl-4-aminopropanyl-Based Inhibitors Targeting Trypanosoma cruzi CYP51 , 2014, Journal of medicinal chemistry.

[38]  P. Hotez,et al.  Global economic burden of Chagas disease: a computational simulation model. , 2013, The Lancet. Infectious diseases.

[39]  M. Jarek,et al.  High-throughput screening and whole genome sequencing identifies an antimicrobially active inhibitor of Vibrio cholerae , 2014, BMC Microbiology.

[40]  D. Sherman,et al.  Identification of New Drug Targets and Resistance Mechanisms in Mycobacterium tuberculosis , 2013, PloS one.

[41]  Michael D. Urbaniak,et al.  Genomic and Proteomic Studies on the Mode of Action of Oxaboroles against the African Trypanosome , 2015, PLoS neglected tropical diseases.

[42]  Rommie E. Amaro,et al.  Comparative chemical genomics reveal that the spiroindolone antimalarial KAE609 (Cipargamin) is a P-type ATPase inhibitor , 2016, Scientific Reports.

[43]  R. Friesner,et al.  Evaluation and Reparametrization of the OPLS-AA Force Field for Proteins via Comparison with Accurate Quantum Chemical Calculations on Peptides† , 2001 .

[44]  T. Poulos,et al.  Crystal structure of cytochrome P450 14α-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. V. Kries,et al.  Identification of Small‐Molecule Scaffolds for P450 Inhibitors , 2010, Current protocols in microbiology.

[46]  J. Castro,et al.  Toxic Side Effects of Drugs Used to Treat Chagas’ Disease (American Trypanosomiasis) , 2006, Human & experimental toxicology.

[47]  J. Baell,et al.  Identification of Compounds with Anti-Proliferative Activity against Trypanosoma brucei brucei Strain 427 by a Whole Cell Viability Based HTS Campaign , 2012, PLoS neglected tropical diseases.

[48]  R. Stroud,et al.  Architecture of a single membrane spanning cytochrome P450 suggests constraints that orient the catalytic domain relative to a bilayer , 2014, Proceedings of the National Academy of Sciences.

[49]  Ronald W. Davis,et al.  Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. , 1999, Science.

[50]  C. Clayton,et al.  Drug Target Identification Using a Trypanosome Overexpression Library , 2014, Antimicrobial Agents and Chemotherapy.

[51]  D. Horn,et al.  Genome-wide RNAi screens in African trypanosomes identify the nifurtimox activator NTR and the eflornithine transporter AAT6 , 2011, Molecular and biochemical parasitology.

[52]  Xiaofeng S Zheng,et al.  Genetic and genomic approaches to identify and study the targets of bioactive small molecules. , 2004, Chemistry & biology.

[53]  S. Lindquist,et al.  The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogs , 2015, Science Translational Medicine.

[54]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[55]  K. Ang,et al.  Trypanosoma cruzi CYP51 Inhibitor Derived from a Mycobacterium tuberculosis Screen Hit , 2009, PLoS neglected tropical diseases.

[56]  S. Yusuf,et al.  Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. , 2015, The New England journal of medicine.

[57]  T. Richardson,et al.  Microsomal P450 2C3 is expressed as a soluble dimer in Escherichia coli following modification of its N-terminus. , 1997, Archives of biochemistry and biophysics.

[58]  Lan V. Zhang,et al.  Knocking out multi-gene redundancies via cycles of sexual assortment and fluorescence selection , 2010, Nature Methods.

[59]  X. Su,et al.  Chemical genomics for studying parasite gene function and interaction. , 2013, Trends in parasitology.

[60]  Ronald W. Davis,et al.  Functional profiling of the Saccharomyces cerevisiae genome , 2002, Nature.

[61]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[62]  Matthew P. Repasky,et al.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.

[63]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[64]  L. Gerena,et al.  Assessment and Continued Validation of the Malaria SYBR Green I-Based Fluorescence Assay for Use in Malaria Drug Screening , 2007, Antimicrobial Agents and Chemotherapy.

[65]  George M. Church,et al.  Genome engineering in Saccharomyces cerevisiae using CRISPR-Cas systems , 2013, Nucleic acids research.

[66]  Mark C. Field,et al.  High-throughput decoding of anti-trypanosomal drug efficacy and resistance , 2011, Nature.

[67]  D. Kelly,et al.  Identification and Characterization of Four Azole-Resistant erg3 Mutants of Candida albicans , 2010, Antimicrobial Agents and Chemotherapy.

[68]  M. Waterman,et al.  Targeting Trypanosoma cruzi sterol 14α-demethylase (CYP51). , 2011, Advances in parasitology.

[69]  Sandhya Kortagere,et al.  Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum , 2014, Nature Communications.

[70]  W. Roush,et al.  Drug Strategies Targeting CYP51 in Neglected Tropical Diseases , 2014, Chemical reviews.